Contents

Search


multiple endocrine neoplasia type-2A (MEN-2A); Sipple syndrome

Also see MEN-2. Pathology: 1) medullary thyroid carcinoma a) begins in childhood b) tumors > 1 cm in size are frequently associated with local or distant metastases c) most common manifestation 2) pheochromocytoma occurs in 50% of patients a) > 50% of patients with unilateral adrenalectomy develop pheochromocytoma in contralateral adrenal b) disproportionate increase in epinephrine relative to norepinephrine 3) parathyroid hyperplasia, hyperparathyroidism (20-30%) 4) cutaneous lichenoid amyloidosis occurs in one form Genetics: - associated with defects in RET, exon 11 codon 634 [2] Laboratory: 1) pentagastrin-stimulation test 2) serum Ca+2, serum albumin, ionized Ca+2 3) serum phosphorus 3) serum parathyroid hormone 4) 24 hour urinary metanephrines 5) DNA analysis for RET proto-oncogene mutations Management: - GLP-1 receptor agonists (incretin mimetics, glutides) are contraindicated in patients with medullary thyroid cancer or MEN2 [3]

Related

medullary thyroid carcinoma pentagastrin stimulation test (calcitonin-stimulation test) pheochromocytoma; paroxysmal hypertension; adrenal medullary paraganglioma; chromoffinoma proto-oncogene tyrosine-protein kinase receptor ret; C-ret; (RET, CDHF12)

General

multiple endocrine neoplasia type-2 (MEN-2)

Properties

ASSOCIATED-NEOPLASM[S]: pheochromocytoma parathyroid adenoma medullary thyroid carcinoma

Database Correlations

OMIM correlations MORBIDMAP 164761

References

  1. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 2052-55
  2. Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 17, 18. American College of Physicians, Philadelphia 1998, 2006, 2015, 2018.
  3. NEJM Knowledge+ Endocrinology